Plinio Mark D. 4
4 · Evelo Biosciences, Inc. · Filed Feb 1, 2022
Insider Transaction Report
Form 4
Plinio Mark D.
Chief Commercial Officer
Transactions
- Award
Common Stock
2022-01-31$4.00/sh+1,250$5,004→ 1,250 total
Footnotes (3)
- [F1]The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Evelo Biosciences, Inc. 2018 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of August 1, 2021 through January 31, 2022. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.
- [F2]The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of January 31, 2022.
- [F3]In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of common stock on the Purchase Date of January 31, 2022.